SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Ambrx Biopharma Inc. AMAM NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Ambrx Biopharma Inc. (AMAM) is a Biotechnology company in the Healthcare sector, currently trading at $28.00. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $7M, -4.5%/yr average growth. Net income is $78M (loss), growing at -92.3%/yr. Net profit margin is -1053.7% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $12M against $118M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 5.44 (strong liquidity). Debt-to-assets is 8.2%. Total assets: $147M.

Analyst outlook: 2 / 6 analysts rate AMAM as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

AMAM SharesGrow Score Overview

34/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 58/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AMAM

No analyst coverage available for this stock.

AMAM: -4.5%/yr revenue is, -92.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet AMAM: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 5.44 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AMAM: Gross margin is 100% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 6 analysts rate AMAM as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

AMAM: Net profit margin is -1053.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range6.55-28.15

Volume1.42M

Avg Volume (30D)1.94M

Market Cap$1.77B

Beta (1Y)-2.36

Share Statistics

EPS (TTM)-2.02

Shares Outstanding$38.61M

IPO Date2023-08-14

Employees87

CEODaniel J. O'Connor

Financial Highlights & Ratios

Revenue (TTM)$7.4M

Gross Profit$7.4M

EBITDA$-55.79M

Net Income$-78M

Operating Income$-57.08M

Total Cash$84.48M

Total Debt$11.98M

Net Debt$-43.63M

Total Assets$146.98M

Price / Earnings (P/E)-13.9

Price / Sales (P/S)239.41

Analyst Forecast

Rating ConsensusHold

Analysts Covering6

Buy 33% Hold 67% Sell 0%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS6418711080

Price Chart

AMAM

Ambrx Biopharma Inc. ↗ · NYSE

Healthcare • Biotechnology

6.55 52WK RANGE 28.15

People Also View

Day One Biopharmaceuticals, Inc.

VectivBio Holding AG

Immix Biopharma, Inc.

Zura Bio Limited

Inozyme Pharma, Inc.

Acumen Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

Elevation Oncology, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message